Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06057610 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase III Study of SHR-A1811 Injection With or Without Pertuzumab in HER2-Positive Recurrent or Metastatic Breast Cancer

StatusActive, Not Recruiting
PhasePhase 3
Started2023-11-01
View on ClinicalTrials.gov ↗

Amendment history

2026-09-08
Study Status v3
Primary completion confirmed: July 2026 (last estimated October 2027)
Primary completion dateestimated 2027-10→confirmed 2026-07-15
Start date2023-10-16→2023-11-01
2026-03-09
Recruiting→Active, Not Recruiting Study Status, Study Design, Contacts/Locations v2
Trial statusRecruiting→Active, Not Recruiting
Enrollment targetestimated 864→confirmed 868
Study sitesdetails revised at 1 of 1 site
2025-04-16
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-10→confirmed 2023-10-16
Study sites0→1
2023-09-21
Original filing
To evaluate the efficacy and safety of SHR-A1811 with or without pertuzumab versus trastuzumab, pertuzumab and docetaxel in HER2-Positive Recurrent or Metastatic Breast Cancer
Trial Details
NCT Number NCT06057610
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions HER2-PositiveRecurrent or Metastatic Breast Cancer
Enrollment 868 participants
Start Date 2023-11-01
Primary Completion 2026-07-15 (estimated)
Study Completion 2032-10 (estimated)
Updated on ClinicalTrials.gov 2026-09-09